Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (OMB#0925-0624). Do not return the completed form to this address.

## **Filling out PDF Forms**

This PDF form contains "roll-over or double-click" help functionality.

This form allows you to enter data directly onto the screen. After completing the form, you are able to print the document so that you can fax/mail the document.

To fill out a form:

- 1. Select the hand tool.
- 2. Position the pointer inside a field, and click to type text.
- 3. After entering text or selecting a check box, do one of the following:
  - Press tab to accept the form field change and go to the next form field.
  - Press Shift+Tab to accept the form field change and go to the previous form field.
  - Press Enter (Windows) or Return (Mac OS) to accept the form field change and deselect the current form field.
- 4. Once completed, print the form.

#### OMB#0925-0624 Expiration Date:12/31/2013

Cancer Trials Support Unit INSTITUTIONAL REVIEW BOARD CERTIFICATION

Attach\_1b\_IRBCRT

## Email, Mail or Fax to:

Cancer Trials Support Unit (CTSU)

ATTN: Coalition of Cancer Cooperative Groups (CCCG) Suite1100, 1818 Market Street

Philadelphia, PA 19103 FAX: 1-215-569-0206

	CTSURegulatory@ctsu.coccg.org			
1) Protocol #: (Lead Group #)	2) Protocol Version Date (Required for Amendments):			
	<u>/m d /d y y y y</u>			
3) Protocol Title:	1			
4) Institution Name (List all institutions covered by IRB approval that will conduct this study. Attach complete list if necessary.)	5) NCI Institution 6 & 6a) OHRP Federalwide Assurance Number			
Indicate # sites on supplemental sheet if applicable:	Code	FWA	FWA Expiration Date (mm/dd/yyyy)	
Ex: University of State	ALXXX	FWA00000123	03/01/2006	
7) Principal Investigator:	8) NCI Invest	igator #:		
7) Timelpai investigator.	8) NCI Investigator #:			
This activity has been reviewed and approved by the IRB in accordance with	th the Common	Rule and any other	governing regulations or subparts:	
9) Approval Type:	10) Review Type:			
Original Amendment Renewal	Full Board Expedited* Facilitated			
11) Expedited Review Categories ( <i>Pick only one for box #10</i> ):	*Provide number from applicable category in box 11) _			
<ul> <li>8.a Where (i) the research is permanently closed to the enrollment of new subjects; (ii) all subjects have completed all research-related interventions; and (iii) the research remains active only for long-term follow-up of subjects</li> <li>8.b Where no subjects have been enrolled and no additional risks have been identified</li> <li>8.c Where the remaining research activities are limited to data analysis</li> <li>11a) Expedited Review (Other) If any other expeditable review category is utilized as the review type, please provide an explanation below:</li> </ul>				
12) Date of IRB or Designee Review from box 10:	13) Approval Period:			
m m d d y y y y	Effective:   Expiration: / / m m d d y y yy m m d d y y y			
14) Was the protocol approved with contingencies? YES NO Provide date all contingencies were approved by the IRB or Designee:  mm dd yyyy	15) NCI CIRB Review (check if NCI CIRB review) Give date of the initial facilitated review by the local IRB or Designee:  mm dd yyyy			
16) OHRP IRB Registration Number (8 digits long): IRB	17) Comments:			
The official signing below certifies that the information provided above is correct and that, as required, future reviews will be performed & certification will be provided. Questions #1 through #20 must be completed for this form to be accepted.  Check here if the person signing this form is an IRB signatory as documented on the institutional assurance with OHRP.  18) Name of IRB Signatory:  19) Name of approving IRB:				
18) Name of IRB Signatory:	,	approving IKB:		
20) Title of IRB Signatory:	21) Phone ()     -			
22) Signature:	23) Date:	/	<u>/</u>	

## **Cancer Trials Support Unit**

# INSTITUTIONAL REVIEW BOARD CERTIFICATION Supplemental Page

Optional page for listing additional sites approved by the local IRB. Please indicate on certification form the number of sites listed on the supplemental form.

## Email, Mail or Fax to:

Cancer Trials Support Unit (CTSU)
ATTN: Coalition of Cancer Cooperative Groups
(CCCG)
Suite1100
1818 Market Street
Philadelphia, PA 19103

FAX: 1-215-569-0206 CTSURegulatory@ctsu.coccg.org

### In Reference to Protocol #:

Additional Institution Names (List all additional institutions covered by IRB approval that will conduct this study.)	NCI Institution Code	OHRP Federal Wide Assurance Number and Expiration Date (mm/dd/yyyy)	
Ex. University of Texas		FWA00000123	09/02/2007